Metabolic Disorders Therapeutics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others), By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Metabolic Disorders Therapeutics Market is projected for substantial growth, expanding from USD 74.81 Billion in 2025 to USD 116.88 Billion by 2031, at a Compound Annual Growth Rate of 7.72%. This market encompasses a broad spectrum of pharmaceutical interventions designed to treat and manage conditions that disrupt normal bodily metabolism, including diabetes, obesity, and lysosomal storage diseases. Its fundamental support stems from the escalating global burden of chronic metabolic conditions, largely driven by aging populations and increasingly sedentary lifestyles. The critical need for these therapeutics is underscored by statistics such as the International Diabetes Federation's projection that approximately 589 million adults aged 20 to 79 will be living with diabetes worldwide in 2025. Despite this robust demand, the market's growth is inherently challenged by the high costs associated with drug development and stringent regulatory approval processes, which frequently delay the commercialization of new treatments and limit market access, especially in developing regions.
Market Driver
The primary catalyst for the expansion of the Global Metabolic Disorders Therapeutics Market is the increasing prevalence of sedentary lifestyles and unhealthy dietary habits, which have led to a significant rise in chronic conditions like obesity and type 2 diabetes, creating a sustained need for long-term pharmacological management. Data from the World Health Organization's 'Lancet Analysis of Global Obesity Trends' in March 2024 indicates that over 1 billion people globally were living with obesity in 2022, emphasizing the urgent demand for effective weight management therapies. Concurrently, the market is significantly propelled by robust research and development pipelines focusing on novel therapeutics. Pharmaceutical entities are increasingly investing in biologics and advanced incretin mimetics, which offer superior efficacy and convenience compared to traditional treatments. The commercial success of recently launched metabolic agents validates this innovation, with Novo Nordisk reporting a 38% increase in sales within its Diabetes and Obesity care division, reaching DKK 215.1 billion in 2023. The broader economic impact of these conditions further incentivizes investment, as the global cost of overweight and obesity is projected by the World Obesity Federation to reach USD 4.32 trillion by 2035.
Market Challenge
The expansion of the Global Metabolic Disorders Therapeutics Market faces significant impediments due to the substantial financial requirements and stringent regulatory frameworks inherent in drug development. Developing novel pharmaceutical interventions for complex metabolic conditions necessitates immense capital investment and prolonged timelines, often with a high risk of failure during clinical trials. This precarious environment discourages manufacturers from pursuing high-risk innovative therapies, potentially leading to a stagnation in the pipeline for advanced treatments and hindering the rapid introduction of diverse therapeutic options needed to meet escalating global demand. Furthermore, the financial burden directly affects market accessibility and volume growth, as companies often price new therapeutics at premium levels to recover massive research expenditures, thereby restricting availability in developing regions where healthcare budgets are limited. The magnitude of this investment intensity is highlighted by the European Federation of Pharmaceutical Industries and Associations' 2024 estimate that the research-based pharmaceutical industry invested approximately 55 billion Euros in R&D in Europe alone, underscoring the economic hurdles to global scalability and commercialization.
Market Trends
The metabolic disorders therapeutics sector is experiencing transformative trends, notably the development of isoform-specific metabolic pathway activators that are reshaping the treatment of metabolic dysfunction-associated steatohepatitis (MASH). These novel therapeutics target specific receptors, such as the thyroid hormone receptor-beta, to reduce liver fibrosis and toxicity without the systemic adverse effects associated with broader hormonal treatments, addressing a critical gap in care. This breakthrough was formally validated by the accelerated FDA approval of Rezdiffra (resmetirom) in March 2024, as reported by Madrigal Pharmaceuticals, establishing a pivotal new standard for noncirrhotic MASH with moderate to advanced liver fibrosis. Simultaneously, there is a definitive shift toward oral biologics and small molecule formulations, aiming to replace invasive injectable regimens with convenient, patient-friendly tablets. This trend prioritizes scalable delivery methods that significantly enhance adherence to long-term chronic disease management protocols. The viability of this next-generation approach is evidenced by promising early-stage clinical successes, such as Roche's investigational oral GLP-1 receptor agonist CT-996, which achieved a mean weight loss of 7.3% in participants with obesity after just four weeks of treatment in Phase I trials in July 2024, underscoring the potent potential of non-injectable metabolic therapies.
Key Market Players
* Novo Nordisk A/S
* Eli Lilly and Company
* Takeda Pharmaceutical Company Limited
* Sanofi SA
* Merck KGaA
* AstraZeneca PLC
* AbbVie Inc.
* Johnson & Johnson Services, Inc
* Amgen Inc.
* BioMarin International Limited
Report Scope
In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Metabolic Disorders Therapeutics Market, By Disease Type
* Lysosomal Storage Diseases
* Diabetes
* Obesity
* Inherited Metabolic Disorders
* Hypercholesterolemia
* Others
# Metabolic Disorders Therapeutics Market, By Therapy Type
* Enzyme Replacement Therapy
* Cellular Transplantation
* Small Molecule Based Therapy
* Substrate Reduction Therapy
* Gene Therapy
* Drug Therapy
# Metabolic Disorders Therapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.
Available Customizations:
Global Metabolic Disorders Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Metabolic Disorders Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Metabolic Disorders Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Therapy Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Therapy Type
6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Therapy Type
6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Therapy Type
7. Europe Metabolic Disorders Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Therapy Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Therapy Type
7.3.2. France Metabolic Disorders Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Therapy Type
7.3.3. United Kingdom Metabolic Disorders Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Therapy Type
7.3.4. Italy Metabolic Disorders Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Therapy Type
7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Therapy Type
8. Asia Pacific Metabolic Disorders Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Therapy Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Metabolic Disorders Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Therapy Type
8.3.2. India Metabolic Disorders Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Therapy Type
8.3.3. Japan Metabolic Disorders Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Therapy Type
8.3.4. South Korea Metabolic Disorders Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Therapy Type
8.3.5. Australia Metabolic Disorders Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Therapy Type
9. Middle East & Africa Metabolic Disorders Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Therapy Type
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Therapy Type
9.3.2. UAE Metabolic Disorders Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Therapy Type
9.3.3. South Africa Metabolic Disorders Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Therapy Type
10. South America Metabolic Disorders Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Therapy Type
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Therapy Type
10.3.2. Colombia Metabolic Disorders Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Therapy Type
10.3.3. Argentina Metabolic Disorders Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Therapy Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Metabolic Disorders Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novo Nordisk A/S
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Eli Lilly and Company
15.3. Takeda Pharmaceutical Company Limited
15.4. Sanofi SA
15.5. Merck KGaA
15.6. AstraZeneca PLC
15.7. AbbVie Inc.
15.8. Johnson & Johnson Services, Inc
15.9. Amgen Inc.
15.10. BioMarin International Limited
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們